DAM
SLNO

DLD Asset Management’s Soleno Therapeutics SLNO Stock Holding History

DLD Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Buy
+10,000
New +$392K 0.03% 223
2025
Q4 		– Sell
-30,000
Closed -$2.03M – 453
2025
Q3 		$2.03M Buy
+30,000
New +$2.22M 0.15% 102

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

DLD Asset Management's SLNO Position: Q1 2026 in Review

DLD Asset Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 5,000 shares — an estimated $196K sold.

DLD Asset Management first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $232K in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • DLD Asset Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DLD Asset Management sold 5,000 Soleno Therapeutics shares in Q1 2026, an estimated $196K.
  • DLD Asset Management first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
  • DLD Asset Management's Soleno Therapeutics position peaked at $232K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on DLD Asset Management's 13F filing for Q1 2026, filed 13 May 2026.